Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

This study found that the epirubicin-docetaxel chemotherapy regimen for metastatic breast cancer resulted in a clinical response in 55% of patients, with maintained global quality of life despite some impairments.

This case report describes a rare instance of alopecia neoplastica, where breast cancer metastasized to the scalp, which can be mistakenly diagnosed as alopecia areata.

This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.